Chemomab Therapeutics (CMMB) EPS (Diluted) Growth (1y) (2018 - 2025)
Chemomab Therapeutics (CMMB) EPS (Diluted) Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 96.09% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 144.25% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 315.14% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -11.18% |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | -55.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 366.99% |
| Sep 30, 2025 | -68.88% |
| Dec 31, 2024 | 7,223,623.74% |
| Sep 30, 2024 | -35.60% |
| Mar 31, 2024 | -58.24% |
| Dec 31, 2023 | -59.90% |
| Sep 30, 2023 | -46.47% |
| Mar 31, 2023 | 276.15% |
| Dec 31, 2022 | 249.37% |
| Sep 30, 2022 | 371.26% |
| Mar 31, 2022 | 99.81% |
| Dec 31, 2021 | 99.94% |
| Sep 30, 2021 | 99.92% |
| Jun 30, 2021 | 99.82% |
| Mar 31, 2021 | -0.53% |
| Dec 31, 2020 | 90.15% |
| Sep 30, 2020 | -569,634.88% |
| Jun 30, 2020 | -2,162,100.00% |
| Mar 31, 2020 | -3,277.35% |
| Dec 31, 2019 | -31,526,012,275.92% |